AbbVie to Make $18 Million Milestone Payment to EvolveImmune Therapeutics After Nomination of Development Candidate
Idag, 16:11
Idag, 16:11
10:11 AM EDT, 04/28/2026 (MT Newswires) -- AbbVie (ABBV) partner EvolveImmune Therapeutics has nominated a development candidate for a next-generation cancer biotherapeutic, triggering a preclinical milestone payment of $18 million from AbbVie, the immuno-oncology company said Tuesday.
The two companies entered into a collaboration and option-to-license agreement to develop multi-specific biologics for multiple targets in oncology in October 2024, according to a statement.
Price: 198.10, Change: +0.72, Percent Change: +0.37
Idag, 16:11
10:11 AM EDT, 04/28/2026 (MT Newswires) -- AbbVie (ABBV) partner EvolveImmune Therapeutics has nominated a development candidate for a next-generation cancer biotherapeutic, triggering a preclinical milestone payment of $18 million from AbbVie, the immuno-oncology company said Tuesday.
The two companies entered into a collaboration and option-to-license agreement to develop multi-specific biologics for multiple targets in oncology in October 2024, according to a statement.
Price: 198.10, Change: +0.72, Percent Change: +0.37
Rapporter
Analys
Rapporter
Analys
1 DAG %
Senast
OMX Stockholm 30
−0,77%
(vid stängning)
Carasent
Idag, 16:30
Carasent: Köpvärd efter förvärvet?
OMX Stockholm 30
1 DAG %
Senast
3 056,01